骨髓纤维化
鲁索利替尼
医学
肝硬化
细胞减少
门脉高压
内科学
胃肠病学
重症监护医学
骨髓
作者
Rui Li,Huasheng Liu,Ying Chen
出处
期刊:PubMed
日期:2023-04-01
卷期号:31 (2): 598-601
标识
DOI:10.19746/j.cnki.issn.1009-2137.2023.02.043
摘要
Primary myelofibrosis (PMF) is easily confused with cirrhosis, due to its main clinical manifestations of splenomegaly and the blood cytopenia. This review focuses on clinical studies to identify primary myelofibrosis and cirrhosis related portal hypertension, to analyze the differences between the two diseases, in order to distinguish PMF and cirrhosis from the pathogenesis, clinical manifestations, laboratory examinations and treatment principles, and simultaneously improve clinicians' understanding of PMF, which is a reference for exploring the early screening or diagnostic indicators of PMF, also provides a clinical basis for the application of new targeted drugs such as ruxolitinib.鉴别原发性骨髓纤维化与肝硬化相关门脉高压的最新研究进展.原发性骨髓纤维化(PMF)在临床上因其多具有脾大体征和血细胞减少等,易与肝硬化相混淆。本综述围绕鉴别原发性骨髓纤维化与肝硬化相关门脉高压的临床研究来分析两种疾病的差异,以期从发病机制、临床表现、实验室检查和治疗原则对比鉴别PMF与肝硬化,同步提升临床医生对PMF的认识,为探索PMF早期筛查或诊断指标予以参考,同时也为芦可替尼等新型靶向药物应用提供临床依据。.
科研通智能强力驱动
Strongly Powered by AbleSci AI